Chloroquine-treated dendritic cells require STAT1 signaling for their tolerogenic activity.

Authors

• Rodolfo Thome
• Amanda Pires Bonfanti
• Javad Rasouli
• Elisabeth Rose Mari
• Guang-Xian Zhang
• Abdolmohamad Rostami
• Liana Verinaud

Publication/Presentation Date

7-1-2018

Abstract

MS and EAE are T cell-driven autoimmune diseases of the CNS where IL-17-producing Th17 cells promote damage and are pathogenic. Conversely, tolerogenic DCs induce Treg cells and suppress Th17 cells. Chloroquine (CQ) suppresses EAE through the modulation of DCs by unknown mechanisms. Here, we show that STAT 1 is necessary for CQ-induced tolerogenic DCs (tolDCs) to efficiently suppress EAE. We observed that CQ induces phosphorylation of STAT1 in DCs in vivo and in vitro. Genetic blockage of STAT1 abrogated the suppressive activity of CQ-treated DCs. Opposed to its WT counterparts, CQ-treated STAT1

Volume

48

Issue

7

First Page

1228

Last Page

1234

ISSN

1521-4141

Published In/Presented At

Thome, R., Bonfanti, A. P., Rasouli, J., Mari, E. R., Zhang, G. X., Rostami, A., & Verinaud, L. (2018). Chloroquine-treated dendritic cells require STAT1 signaling for their tolerogenic activity. European journal of immunology, 48(7), 1228–1234. https://doi.org/10.1002/eji.201747362

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

29572810

Department(s)

Administration and Leadership

Document Type

Article